Approval · Notice of Compliance 5987 · 2004
EBIXA: Notice of Compliance 5987
Issued December 8, 2004
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
Issued with conditions (NOC/c): the company must confirm the benefit in further studies.
- Notice number
- 5987
- Date
- December 8, 2004
- Company
- Lundbeck Canada IncSt-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
- Therapeutic class
- N-methyl-d-aspartate (nmda) receptor antagonist
- With conditions
- Yes (NOC/c)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| EBIXA | 02260638 | Cancelled Post Market |
Medicinal ingredients
- MEMANTINE HYDROCHLORIDE 10 MG per TAB